NCT00375661View on ClinicalTrials.gov

Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2013

Conditions
Hepatitis C, Chronic
Interventions
DRUG

interferon-alfa-2b and ribavirin

Interferon, pnce per week plus daily ribavirin

Trial Locations (2)

Unknown

Department of Gastroenterology and Hepatology, Kyoto University Hospital, Kyoto

Osaka Red Cross Hospital, Osaka

All Listed Sponsors
lead

Kyoto University

OTHER

NCT00375661 - Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC | Biotech Hunter | Biotech Hunter